]>
IRCT20190817044550N4 IRCT 2023-06-18 Birjand University of Medical Sciences Comparison of Deferazirox and Deferoxamine on Serum Ferritin Levels Changes in Major Beta Thalassemia Patients Comparison of Deferazirox and Deferoxamine on Serum Ferritin Levels Changes in Major Beta Thalassemia Patients 2022-10-23 anticipated 45 Complete https://irct.ir/trial/70507 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: We used the permuted block randomization method, and these blocks were randomly designed in Excel software, and then groups equal to the allocation of a as the intervention group and b as the control group were performed. N/A beta thalassemia major. Intervention 1: Intervention group: Treated with deferasirox (Nanojade) ± Deferiprone. Intervention 2: Intervention group: Treated with deferoxamine (Desferal) ± deferiprone. No - There is not a plan to make this available Justification or reason for not sharing IPD is The data obtained from this project will eventually be reported as standard and general, and reporting personal information by individuals does not seem necessary.
public Saeedeh Khorashadi zadeh
Ghaffari St., Birjand University of Medical Sciences
Birjand Iran (Islamic Republic of) 9717853577 +98 56 3162 2001 saedehkhorashadi4590@gmail.com Birjand University of Medical Sciences scientific Tayyebeh Chahkandi
Ghaffari St., Birjand University of Medical Sciences
Birjand Iran (Islamic Republic of) 9717853577 +98 56 3162 2001 na_chahkandi@yahoo.com Birjand University of Medical Sciences Iran (Islamic Republic of) The age of the patients was 2 years and older Have a normal serum creatinine level Absence of proteinuria in U/A patients The serum ferritin levels of the patients should be above 1000 mg/dl, or the patients should have had more than 10 blood transfusions, or the volume of blood transferred should be more than 100 cc/kg 2 years no limit Both Pregnancy and breastfeeding Resistant levels greater than 5 times the normal value of liver transaminase Severe nausea and vomiting in the patient Patient refusal to participate in the study D56.1 Beta thalassemia Treatment - Drugs Treatment - Drugs Intervention group: Treated with deferasirox (Nanojade) ± Deferiprone Intervention group: Treated with deferoxamine (Desferal) ± deferiprone Serum ferritin level. Timepoint: Measurement of serum ferritin level at the beginning of the study (before the start of the intervention), 3 and 6 months after the start of the intervention. Method of measurement: Biochemical test. Birjand University of Medical Sciences Approved 2022-10-10 Ethics Committee of Birjand University of Medical Sciences Birjand University of Medical Sciences, Ghaffari Street Birjand South Khorasan Iran (Islamic Republic of)